Silo Pharma Announces 1-for-15 Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

Silo Pharma announced a 1-for-15 reverse stock split, effective June 2, 2026, to boost its share price and maintain its Nasdaq listing, confirming earlier news reports.

check_boxKey Events · Corporate Governance and Compliance · SILO

• 1-for-15 Reverse Stock Split Announced

  Silo Pharma will effect a 1-for-15 reverse stock split of its common stock, effective June 2, 2026, with post-split trading commencing on June 3, 2026, under the same 'SILO' ticker.

• Shares Outstanding Reduced

  The reverse split will reduce the number of issued and outstanding shares from approximately 16.267 million to approximately 1.084 million, with fractional shares rounded up.

• Authorized Shares Proportionately Reduced

  The company's authorized common stock will be proportionately reduced to 6,666,667 shares after the split.

• Nasdaq Listing Compliance

  This action is typically undertaken by companies with low stock prices to meet exchange minimum bid price requirements and avoid delisting, a common challenge for micro-cap companies with ongoing losses.

auto_awesomeAnalysis · SILO · Life Sciences

Silo Pharma is implementing a 1-for-15 reverse stock split, effective June 2, 2026, to increase its per-share price and meet Nasdaq's minimum bid price requirements. This action, which follows recent news reports, is a critical step for the micro-cap company to avoid potential delisting, especially given its history of net losses and financial challenges highlighted in recent 10-K and 10-Q filings. While necessary for listing compliance, reverse splits are generally viewed negatively by the market as they often signal underlying business struggles.